Atea Pharmaceuticals, Inc. - common stock (NQ:AVIR)

3.020 +0.040 (+1.34%)

Streaming Delayed Price Updated: 10:48 AM EST, Nov 25, 2025 Add to My Watchlist

Price and Volume

Volume	43,394
Open	3.000
Bid (Size)	3.010 (600)
Ask (Size)	3.020 (200)
Prev. Close	2.980
Today's Range	2.985 - 3.060
52wk Range	2.455 - 4.020
Shares Outstanding	83,399,377
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

November 19, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharma (AVIR) Earnings Call Transcript ↗

November 13, 2025

Atea Pharma (AVIR) Earnings Call Transcript

Via The Motley Fool

Performance

YTD	-11.7%	-11.7%
1 Month	-7.1%	-7.1%
3 Month	-17.5%	-17.5%
6 Month	+2.4%	+2.4%
1 Year	-11.2%	-11.2%

More News

Atea Pharmaceuticals Inc (NASDAQ:AVIR) Reports Q3 2025 Financial Results and Business Update ↗

November 12, 2025

Via Chartmill

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Earnings Scheduled For November 12, 2025 ↗

November 12, 2025

Via Benzinga

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

Atea Pharmaceuticals Earnings Preview ↗

November 11, 2025

Via Benzinga

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

November 07, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

November 05, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

October 22, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

October 07, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

September 02, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea (AVIR) Q2 Loss Narrows 8% ↗

August 07, 2025

Via The Motley Fool

Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

August 07, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

July 31, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

June 24, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

May 07, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

May 01, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025

April 23, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

April 17, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Top movers in Wednesday's pre-market session ↗

April 09, 2025

Via Chartmill

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

April 09, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value

March 26, 2025

From Atea Pharmaceuticals, Inc.

Via GlobeNewswire

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

March 26, 2025

From On Behalf of The Radoff-JEC Group

Via Business Wire

Frequently Asked Questions

Is Atea Pharmaceuticals, Inc. - common stock publicly traded?

Yes, Atea Pharmaceuticals, Inc. - common stock is publicly traded.

What exchange does Atea Pharmaceuticals, Inc. - common stock trade on?

Atea Pharmaceuticals, Inc. - common stock trades on the Nasdaq Stock Market

What is the ticker symbol for Atea Pharmaceuticals, Inc. - common stock?

The ticker symbol for Atea Pharmaceuticals, Inc. - common stock is AVIR on the Nasdaq Stock Market

What is the current price of Atea Pharmaceuticals, Inc. - common stock?

The current price of Atea Pharmaceuticals, Inc. - common stock is 3.020

When was Atea Pharmaceuticals, Inc. - common stock last traded?

The last trade of Atea Pharmaceuticals, Inc. - common stock was at 11/25/25 10:48 AM ET

What is the market capitalization of Atea Pharmaceuticals, Inc. - common stock?

The market capitalization of Atea Pharmaceuticals, Inc. - common stock is 251.87M

How many shares of Atea Pharmaceuticals, Inc. - common stock are outstanding?

Atea Pharmaceuticals, Inc. - common stock has 252M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.